Fosun Pharma stock has HKD 21.93 consensus target from six ratings

Published on 10/17/2026 at 18:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 4.75 percent in the first half of 2026. Fosun Pharma stock costs EUR 1.93 on October 16, 2026, down 1.88 percent versus the Tradegate close.

Targets, earnings and trading

On October 9, 2026, six ratings implied an average HKD 21.93 target.
First-half 2026 revenue reached CNY 20.442 billion, up 4.75 percent year over year.
Fosun Pharma stock stood at EUR 1.93 on Tradegate on October 16, 2026 at 8:02 p.m. CEST, down 1.88 percent versus the Tradegate close of October 15, 2026.
Fosun Pharma has October 27, 2026 results on its calendar.

Fosun Pharma, CNE100001M79, Illustration mit AI erstellt.

Six analyst ratings point to an average HKD 21.93 target for Fosun Pharma, 28.17 percent above the HKD 17.11 home-market price on October 16, 2026, according to Barron's. The euro quotation stood at EUR 1.93 on Tradegate on October 16, 2026 at 8:02 p.m. CEST, down 1.88 percent versus the Tradegate close of October 15, 2026 at EUR 1.96.

Analyst target leaves room

The average target implies a 28.17 percent distance from the latest HKD 17.11 home-market price. The rating picture therefore gives investors a measurable valuation reference, while the target itself remains in Hong Kong dollars and is not a euro price.

First-half revenue grew 4.75 percent

Fosun Pharma reported CNY 20.442 billion of revenue for the first half of 2026, an increase of 4.75 percent from the year-earlier period. Net profit attributable to shareholders after non-recurring items reached CNY 1.144 billion, up 19.09 percent year over year, while operating cash flow rose 13.59 percent to CNY 2.424 billion, according to PatSnap.

Price position on October 16

The HKEX quote was HKD 17.11 on October 16, 2026, with a 52-week range of HKD 14.90 to HKD 24.72. The price was 30.79 percent below the high and 14.83 percent above the low. Trading volume was 2,253,000 shares against an average of 3,531,058 shares.

Valuation and October results

Fosun Pharma had a market capitalization of HKD 64.1 billion, a trailing price-to-earnings ratio of 17.95 and a dividend yield of 2.00 percent on October 16, 2026. The company lists October 27, 2026 as its next results date on its investor-relations page, which also identifies the primary listings as 600196 on the Shanghai exchange and 02196 on the Hong Kong exchange, according to Fosun Pharma.

Comparison with peers

Fosun Pharma (HKEX, HKD): minus 1.88 percent, P/E 17.95, market capitalization HKD 64.1 billion

Sino Biopharmaceutical (HKEX, HKD): minus 0.38 percent, P/E 33.78, market capitalization HKD 93.5 billion

CSPC Pharmaceutical Group (HKEX, HKD): plus 0.17 percent, P/E 11.62, market capitalization HKD 101.3 billion

Stock stays between key levels

For investors, the clearest reference points are the HKD 21.93 average target and the HKD 14.90 to HKD 24.72 yearly range. Fosun Pharma's next scheduled results date is October 27, 2026.